Dysphagia News and Research

RSS

Dysphagia is the medical term for the symptom of difficulty in swallowing. Although classified under "symptoms and signs" in ICD-10, the term is sometimes used as a condition in its own right. Sufferers are sometimes unaware of their dysphagia.

FDA approves Allergan’s BOTOX to treat overactive bladder

Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

19 Jan 2013

Make palliative care available to Parkinson's patients

A modified version of the Edmonton Symptom Assessment System Scale is quick and effective at assessing patients with late-stage Parkinson's disease, and reveals that they have similar levels of symptoms as their peers with metastatic cancer, show study results from Canada.

28 Dec 2012

Food hardness affects bolus size, swallowing

The smaller the particles in a food bolus, the harder the food is likely to be, report researchers in the Archives of Oral Biology.

22 Nov 2012

Dysphagia is an easier pill to swallow with video technology

Video-assisted swallowing therapy significantly improves swallowing-associated outcomes in cognitively intact Parkinson’s disease patients, research suggests.

14 Nov 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

Tonsillectomy does not lead to unhealthy weight in children

Tonsillectomy leads to weight gain in children, but does not increase the likelihood of overweight or obesity, report researchers.

23 Oct 2012

Liquid version of breast cancer drug Tamoxifen launched in the US

Breast Cancer Awareness Month raises visibility and research dollars to address a disease that in the United States claims nearly 40,000 lives annually and affects approximately 240,000 people who each year are newly diagnosed. While the month's activities are important in the fight against breast cancer, they are not designed to directly improve the day-to-day management of the disease.

22 Oct 2012

Dopaminergic treatment has ‘minor impact’ on autonomic symptoms in Parkinson’s

Norwegian researchers say that dopaminergic treatment should be considered for patients with early Parkinson’s disease after finding that dopaminergic medication only has a minor impact on autonomic symptoms after 1 year.

17 Oct 2012

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

Sterotactic radiotherapy offers good results in recurrent head and neck cancer

For patients with recurring head and neck cancer, stereotactic body radiotherapy offers a feasible and tolerable salvage treatment, with median overall survival rates of more than 1 year, report researchers.

30 Aug 2012

Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis

Meritage Pharma, Inc. announced that it has initiated a Phase 2 clinical trial to evaluate oral budesonide suspension (OBS) for the treatment of adolescents and young adults with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. EoE is a chronic disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation.

13 Aug 2012

Esophageal biopsy advised in children with foreign body impaction

Study findings suggest that a considerable number of children with esophageal foreign body or food bolus impaction have eosinophilic esophagitis.

24 Jul 2012

HNCA post-treatment depression impairs life quality

Individuals undergoing treatment for head and neck cancer have a high incidence of depression, US researchers show.

18 Jul 2012

Transcranial direct current stimulation can enhance outcome of swallowing therapy for post-stroke dysphagia

After stroke, patients often suffer from dysphagia, a swallowing disorder that results in greater healthcare costs and higher rates of complications such as dehydration, malnutrition, and pneumonia.

2 Jul 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder

Allergan, Inc. today announced that two Phase III clinical trials of BOTOX (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints.

29 Mar 2012

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.

12 Mar 2012

ViroPharma to acquire Meritage

ViroPharma Incorporated today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus.

23 Dec 2011